Calls Now Open
2022 ADDF-Harrington and 2023 Harrington UK Rare Disease Programs
Frank Richardson, DVM, PhD, DABT has logged over 25 years in both large pharmaceutical and biotechnology drug development activities, including toxicologic assessment of drug candidates, biomarker development, and animal care and use. He has conducted all aspects of preclinical toxicology and biomarker development from discovery to product registration with emphasis on oncology and antiviral compounds.
Former Principal Toxicologist, Affygility Solutions
Former Principal Research Fellow in Toxicology and Molecular Markers, OSI Pharmaceuticals
Former Director of Toxicology Safety Assessment and Animal Facility, Gilead Pharmaceuticals